GrandOmics Biosciences Expands Investment in PacBio’s Sequel Systems for Precision Medicine Initiative
January 04 2017 - 7:30AM
Pacific Biosciences of California, Inc. (Nasdaq:PACB), today
announced that GrandOmics Biosciences Co., Ltd of Beijing, through
its subsidiary NextOmics in Wuhan, has agreed to purchase five
additional Sequel™ instruments to support China’s precision
medicine initiative, with a specific focus on ultimately providing
the genetic diagnosis of inherited diseases.
GrandOmics was one of the early commercial sequencing service
providers in China to purchase a Sequel System, and previously
provided services for de novo genome assembly and full-length
transcriptome analysis based on their bioinformatics expertise
using the PacBio® RS II system. Both instruments are based on
PacBio’s Single Molecule, Real-Time (SMRT®) Sequencing
technology.
“GrandOmics is one of a growing number of customers who have
placed multi-instrument orders for the Sequel System,” said Dr.
Michael W. Hunkapiller, Chief Executive Officer of Pacific
Biosciences. “As one of the early users of the Sequel System, they
have experienced the performance gains achieved through software
and chemistry upgrades, and we appreciate the confidence they have
shown in the platform by purchasing multiple additional systems. We
believe this is a great endorsement of how well-suited SMRT
technology and the Sequel System are for a wide range of
applications from de novo genome assembly to clinical
research.”
GrandOmics, together with its subsidiary NextOmics, have
experience with a number of clinical research applications using
SMRT Sequencing technology. For example, they participated in the
HuaXia project to construct the first published, near-complete
Asian genome, and developed several approaches, ranging from
full-length HLA typing and trinucleotide repeat expansion
quantification, to the detection of complex structural variants in
inherited diseases.
“We were one of the first Chinese sequencing service providers
to focus on PacBio SMRT Sequencing technology, and we have helped
our customers complete hundreds of genome and transcriptome
sequencing projects on animal, plant, microbial and human genomes
since 2012,” said Mr. Depeng Wang, Chief Executive Officer of
GrandOmics. “We plan to deploy our six Sequel Systems in Wuhan and
Beijing, and establish a genomics service center based in the US
next year to provide services to customers worldwide.”
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
offers sequencing systems to help scientists resolve genetically
complex problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences’ products enable: de novo
genome assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences’ technology
provides high accuracy, ultra-long reads, uniform coverage, and is
the only DNA sequencing technology that provides the ability to
simultaneously detect epigenetic changes. PacBio® sequencing
systems, including consumables and software, provide a simple,
fast, end-to-end workflow for SMRT Sequencing. More information is
available at www.pacb.com.
About GrandOmics
GrandOmics Biosciences Co., Ltd is a Beijing-based
biotechnology company specializing in using cutting-edge sequencing
platforms to perform genome research on non-human species and to
implement precision medicine on human genetic diseases. As one of
the first providers of third-generation sequencing services in
China based on PacBio SMRT Sequencing, GrandOmics has worked with
hundreds of customers worldwide, and provided genomic solutions to
address the complexity of genomes that cannot be handled by
traditional short-read sequencing platforms. Currently, GrandOmics,
together with its subsidiary NextOmics, have recruited nearly 100
employees in Beijing and Wuhan, deployed multiple PacBio Sequel
sequencers, along with BioNano Irys and 10x Genomics Chromium
platforms, and are building two clinical diagnostic laboratories.
GrandOmics is rapidly becoming a world leader in sequencing
services and precision medicine using PacBio long-read sequencing
technology. For more information, please visit the official
website: www.grandomics.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to product orders, future uses, quality or
performance of, or benefits of using, products or technologies, the
expected benefits of the company’s agreement with GrandOmics’
subsidiary NextOmics, the suitability of the company’s products for
the clinical research and sequencing market or other markets and
other future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences’ most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts
Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com
Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024